Current status of PI3K/AKT/mTOR pathway and its inhibitors in breast cancer

卢训西; 国琳玮; 李小光; 胡　欣

doi:10.19401/j.cnki.1007-3639.2020.02.011

您当前的位置：

首页 >

文章列表页 >

Current status of PI3K/AKT/mTOR pathway and its inhibitors in breast cancer

更新时间：2026-01-27

- Current status of PI3K/AKT/mTOR pathway and its inhibitors in breast cancer
- China Oncology Vol. 30, Issue 2, Pages: 154-160(2020)
- 作者机构：
  
  复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系,上海,200030
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.02.011
  CLC： R737.9
- Published Online：09 March 2020，
  
  Published：09 March 2020
- 稿件说明：
移动端阅览
卢训西, 国琳玮, 李小光, 胡　欣. PI3K/AKT/mTOR通路及其抑制剂在乳腺癌中的应用现状[J]. 中国癌症杂志, 2020, 30(2): 154-160.

卢训西, 国琳玮, 李小光, et al. Current status of PI3K/AKT/mTOR pathway and its inhibitors in breast cancer[J]. China Oncology, 2020, 30(2): 154-160.
卢训西, 国琳玮, 李小光, 胡　欣. PI3K/AKT/mTOR通路及其抑制剂在乳腺癌中的应用现状[J]. 中国癌症杂志, 2020, 30(2): 154-160. DOI： 10.19401/j.cnki.1007-3639.2020.02.011.

卢训西, 国琳玮, 李小光, et al. Current status of PI3K/AKT/mTOR pathway and its inhibitors in breast cancer[J]. China Oncology, 2020, 30(2): 154-160. DOI： 10.19401/j.cnki.1007-3639.2020.02.011.

摘要

磷脂酰肌醇3-激酶（phosphoinositide 3-kinase，PI3K）/蛋白激酶B（protein kinase B，AKT）/哺乳动物雷帕霉素靶蛋白（mammalian target of rapamycin，mTOR）信号转导通路在多种肿瘤中异常激活，参与肿瘤细胞增殖、分化和凋亡等生命过程的调控，是抗肿瘤药物研发的重要靶点。对目前已应用于乳腺癌临床或处于临床试验阶段的PI3K/AKT/mTOR信号通路抑制剂进行归纳，并综述该通路抑制剂的联合用药策略，以期为不同亚型乳腺癌提供个体化靶向治疗方案。

Abstract

The abnormal activation of phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway takes place in a variety of tumors. This pathway

which is an important target for the development of anti-tumor drugs

mediates the regulation of tumor cell proliferation

differentiation and apoptosis. This article summarized the PI3K/AKT/mTOR pathway inhibitors used in clinical practice and undergoing clinical trials

and also reviewed the combination strategy of several pathway inhibitors with other targeted drugs

which may offer personalized approach for the treatment of different breast cancer subtypes.

关键词

Keywords

references

Views

5542

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

A study of 30-year trends in incidence and mortality risks of breast cancer among young women in China

Impact of miR-193a-3p on migration and invasion of breast cancer stem cells through targeting TRIM14

Axillary management after neoadjuvant therapy for breast cancer and optimization of sentinel lymph node diagnosis and treatment

Related Author

The Society of Breast Cancer China Anti-Cancer Association

Breast Oncology Group of the Oncology Branch of the Chinese Medical Association

LU Ye

ZHANG Wenxiang

KONG Xiangyi

FANG Yi

WANG Jing

GAO Jidong

Related Institution

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital& Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Shanghai Engineering Research Center of Artificial Intelligence Technology for Tumor Diseases

Department of Laboratory Medicine, Xingtai People’s Hospital

AI问答

⁰